Double-blind randomized and controled trial of beta-blocker effect in the prevention of Chemotherapy-induced Cardiomyopathy

• Grant number: 10/18078-8
• Support Opportunities: Research Projects - Thematic Grants
• Start date: November 01, 2011
• End date: July 31, 2018
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Edimar Alcides Bocchi
• Grantee: Edimar Alcides Bocchi
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Fátima das Dores da Cruz ; Ludmilla Thomé Domingos Chinen ; Marcello Ferretti Fanelli ; Silvia Moreira Ayub Ferreira ; Solange Moraes Sanches

Abstract

Chemotherapy-induced Cardiomyopathy (CIC) accounts for approximately 1% of all dilated cardiomyopathies. In the case of the anthracycline, class of chemotherapy drugs used to treat a variety of hematologic malignancies and solid organs, there is some degree of ventricular dysfunction in half of patients after 10 to 20 years of treatment and symptomatic heart failure developed in 10% of patients receiving doses greater than 550 g/m 2 of doxorubicin. The search for means for the prevention of cardiotoxicity is relevant. The chemotherapy that can potentially increase survival of cancer patients may lead to the development of heart failure (HF), a disease that can be more severe and had a lower life expectancy, since the survival of patients with HF grade IV is worse than most cancers. Initial studies showed beneficial effect of carvedilol to prevent CIC. Therefore this trial intends to study the effectiveness of carvedilol for the prevention of CIC. It will be selected 200 patients with indication for neoadjuvant or adjuvant therapy for primary breast cancer involving anthracyclines. These patients will be randomized to carvedilol or placebo and underwent evaluation of cardiac function at the beginning of treatment and after completing chemotherapy. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

AVILA, MONICA SAMUEL; AYUB-FERREIRA, SILVIA MOREIRA; DE BARROS WANDERLEY, JR., MAURO ROGERIO; CRUZ, FATIMA DAS DORES; GONCALVES BRANDAO, SARA MICHELLY; CARVALHO RIGAUD, VAGNER OLIVEIRA; HIGUCHI-DOS-SANTOS, MARILIA HARUMI; HAJJAR, LUDHMILA ABRAHAO; KALIL FILHO, ROBERTO; HOFF, PAULO MARCELO; et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity. Journal of the American College of Cardiology, v. 71, n. 20, p. 2281-2290, MAY 22 2018. (10/18078-8)